Who absolutely should not take semaglutide?
Three groups, according to the Wegovy label:
- Personal or family history of medullary thyroid cancer (MTC). This is a rare thyroid cancer that starts in the C-cells. If a relative had thyroid cancer and you do not know which type, find out before starting.
- Multiple endocrine neoplasia type 2 (MEN 2). An inherited syndrome that raises the risk of MTC.
- A prior serious allergic reaction to semaglutide or any ingredient in the product, such as anaphylaxis or swelling of the face and throat.
The thyroid exclusions come from the boxed warning. Semaglutide caused thyroid C-cell tumors in mice and rats, and it is unknown whether it does so in people. Because the human risk cannot be ruled out, people with the highest background risk are excluded. Our page on semaglutide and thyroid cancer risk covers the evidence.
Why does past pancreatitis matter?
Because pancreatitis is one of the label’s warnings, and a past episode raises the stakes. Acute pancreatitis, including rare severe and fatal forms, has been seen with GLP-1 medicines. In the weight trials it was uncommon, confirmed in 4 semaglutide patients versus 1 on placebo, but the label tells clinicians to stop the drug if it is suspected.
MedlinePlus advises telling your clinician before starting if you have ever had pancreatitis. A past episode from a clear, resolved cause such as gallstones is weighed differently from repeated or unexplained attacks, and that judgment belongs in the consultation.
Why does gallbladder disease matter?
Because semaglutide raises the odds of gallstones and gallbladder inflammation. The label reports gallstones in 1.6% of adults on semaglutide injection versus 0.7% on placebo, and gallbladder inflammation in 0.6% versus 0.2%. Rapid weight loss raises the risk on its own, but the rates stayed higher than placebo even after accounting for weight loss.
If you have had gallbladder attacks, your provider will want to know when and how they were treated. The NIDDK describes a typical attack as pain in the upper right abdomen that can last several hours, often after heavy meals. More on that in GLP-1 medicines and gallbladder problems.
Why does diabetic eye disease matter?
Because rapid improvement in blood sugar can temporarily worsen diabetic retinopathy. In a two-year trial of semaglutide in people with type 2 diabetes, retinopathy complications occurred in 3% on semaglutide versus 1.8% on placebo. The increase was larger in people who already had retinopathy: 8.2% versus 5.2%. The label asks that people with a history of diabetic retinopathy be monitored for progression, which usually means an eye exam plan before and during treatment.
Vision questions also come up for other reasons; see semaglutide and sudden vision loss.
Other situations that need extra caution
Several other situations call for a careful look rather than an automatic no:
| Situation | Why it matters |
|---|---|
| Severe gastroparesis | The label does not recommend semaglutide, since it slows stomach emptying further |
| Kidney disease | Vomiting and diarrhea can cause dehydration and kidney injury, and the risk was higher with existing kidney problems |
| Insulin or sulfonylurea use | Higher risk of low blood sugar unless doses are adjusted |
| Past bariatric surgery | Serious low blood sugar was more common in trial patients with a history of weight-loss surgery |
| Another GLP-1 or tirzepatide | The label does not recommend combining them |
| Upcoming surgery with anesthesia | Food can stay in the stomach, raising aspiration risk, so your surgical team needs to know |
Related question: who is a good fit instead?
Semaglutide for weight is approved for adults with obesity, or with overweight plus at least one weight-related condition, alongside diet and activity. Our page on who qualifies for semaglutide explains how those criteria are applied.
How Ultimate Male screens before semaglutide
At Ultimate Male, screening happens before any dose is discussed. The consultation with a PA-C or MD covers your personal and family history, including thyroid cancer, pancreatitis, gallbladder and eye disease, plus every medicine you take. On-site blood work before semaglutide or tirzepatide adds kidney function, blood sugar and other markers to the picture.
If semaglutide is not safe for you, the visit does not end there. The medical weight loss program can look at tirzepatide where appropriate, or at a plan built on nutrition, training and monitoring. A consultation is an evaluation, not a promise of a medicine. The free 10-minute call at 626-319-5261 is a good place to raise your history first.
